Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04733989 · ClinicalTrials.gov registry record
A Biomarker Database to Investigate Blood-Based and Digital Biomarkers in Participants Screened for Alzheimer's Disease (Bio-Hermes)
A clinical trial, sponsored by GAP Innovations, PBC.
- Completed
- Registry status
- 1,002
- Enrollment target
NCT04733989: Completed study, sponsored by GAP Innovations, PBC.
NCT04733989 is a clinical trial that has completed, run by GAP Innovations, PBC. The registered enrollment target is 1,002 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04733989 has completed, sponsored by GAP Innovations, PBC.
- COMPLETED
- Registry status
- 1,002 participants
- Enrollment target
Study Summary
The purpose of this study (Bio-Hermes) is to develop a blood, digital, and brain amyloid PET scan biomarker database that can be used to determine whether a meaningful relationship exists between digital tests, blood amyloid-beta, p-tau, and neurofilament biomarker levels and amyloid-beta levels identified through brain amyloid PET images. Blood collected will also be genetically sequenced to gain insights about genes and brain amyloid. The Bio-Hermes study will include 1,000 volunteers over the age of 60 screened for Preclinical Alzheimer's Disease, Prodromal AD, or Mild Dementia AD, and includes an endpoint enrollment requirement of 200 participants from underrepresented minority populations.
Interventions
- OTHER Biomarker Data Collection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,002 participants |
| Start Date | 2021-04-21 |
| Est. Completion | 2022-11-11 |
What the finished NCT04733989 record still lists
NCT04733989 is an observational study that tracks outcomes without assigning an intervention. Its 1,002 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which Biomarker Data Collection is the first listed.
NCT04733989 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04733989 about?
NCT04733989 is a clinical study titled "A Biomarker Database to Investigate Blood-Based and Digital Biomarkers in Participants Screened for Alzheimer's Disease (Bio-Hermes)". The purpose of this study (Bio-Hermes) is to develop a blood, digital, and brain amyloid PET scan biomarker database that can be used to determine whether a meaningful relationship exists between digital tests, blood amyloid-beta, p-tau, and neurofilament biomarker levels and amyloid-beta levels ide...
What is the current status of trial NCT04733989?
This trial is currently completed. The enrollment target is 1,002 participants. The study started on 2021-04-21. Estimated completion is 2022-11-11.
What interventions are being tested in trial NCT04733989?
The interventions under investigation include: Biomarker Data Collection (OTHER).
Who is sponsoring clinical trial NCT04733989?
This trial is sponsored by GAP Innovations, PBC, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06207864 · 1,001 participants · NA
Engagement of American Indians of Southwestern Tribal Nations in Cancer Genome Sequencing
- NCT00018044 · 1,000 participants
Study of Mycobacterial Infections
- NCT01036581 · 1,000 participants · NA
Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging
- NCT01192048 · 1,000 participants
Genetics of Congenital Heart Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI